PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16628227-10 2006 Notably, olomoucine effectively prevented amifostine and/or Adp53-induced Cdc2 kinase activation and subsequent apoptosis. olomoucine 9-19 cyclin dependent kinase 1 Homo sapiens 74-78 23399722-1 2013 A series of 2,9-substituted 6-guanidinopurines, structurally related to the cyclin-dependent kinase (CDK) inhibitors olomoucine and roscovitine, has been synthesized and characterized. olomoucine 117-127 cyclin dependent kinase 1 Homo sapiens 101-104 11958860-7 2002 The CDK-1 inhibitor olomoucine prevented the cytotoxicity of Abeta 31-35 containing peptides in differentiated human teratocarcinoma cell line, Ntera 2/cl-D1 (NT-2) neurons. olomoucine 20-30 cyclin dependent kinase 1 Homo sapiens 4-9 15130771-5 2004 Herein we demonstrate that three 2,6,9-trisubstituted purines: olomoucine, roscovitine, and purvalanol, used at concentrations ascribed by others to potently inhibit CDKs 1, 2, and 5, are powerful triggers of death in maturing cerebellar granule neurons, assessed by loss of mitochondrial reductive capacity and differential staining with fluorescent indicators of living/dead neurons. olomoucine 63-73 cyclin dependent kinase 1 Homo sapiens 166-170 12920193-8 2003 The neuroprotective and antiproliferative actions of cAMP, however, were closely mimicked by olomoucine and roscovitine, potent inhibitors of the cyclin-dependent kinase CDK1 that are structurally related to cAMP. olomoucine 93-103 cyclin dependent kinase 1 Homo sapiens 170-174 16427064-9 2006 The phosphorylation was suppressed by treatment of cells with olomoucine of an inhibitor specific for cyclin dependent kinase (Cdk-1). olomoucine 62-72 cyclin dependent kinase 1 Homo sapiens 127-132 15709490-4 2005 Mutation of the serine 26 residue and inhibition of Abeta phosphorylation by the CDK-1 inhibitor olomoucine prevented Abeta toxicity, suggesting that the phosphorylated Abeta peptide represents a toxic intermediate. olomoucine 97-107 cyclin dependent kinase 1 Homo sapiens 81-86 11726805-5 2001 In NT-2 neurons the levels of pSAbeta were increased in the presence of exogenous Abeta and this increase was prevented by a cdc2 protein kinase inhibitor, olomoucine, that also prevented Abeta cytotoxicity. olomoucine 156-166 cyclin dependent kinase 1 Homo sapiens 125-129 10567774-2 1999 In this study we investigated the cellular effects of olomoucine in two human Burkitt"s lymphoma cell lines, WMN (containing wild-type p53) and CA46 (containing mutant p53), and found that in consistency with its ability to block the activity of cyclin E/Cdk2 and cyclin B1/Cdc2 kinases, olomoucine caused cell cycle arrest at both G1/S and G2/S boundaries. olomoucine 54-64 cyclin dependent kinase 1 Homo sapiens 274-278 11237594-7 2001 Addition of olomoucine, a specific inhibitor of CDK2 and CDC2 activity on the other hand reduces the expression of the reporter. olomoucine 12-22 cyclin dependent kinase 1 Homo sapiens 57-61 10896313-0 2000 Structure-based design of potent CDK1 inhibitors derived from olomoucine. olomoucine 62-72 cyclin dependent kinase 1 Homo sapiens 33-37 10500810-6 1999 Olomoucine (OC), flavopiridol (FP), butyrolactone I (BL) and their derivatives selectively inhibit CDKs and thus constrain tumor cell proliferation under in vitro and/or in vivo conditions. olomoucine 0-10 cyclin dependent kinase 1 Homo sapiens 99-103 10465404-1 1999 Novel C-2, C-6, N-9 trisubstituted purines derived from the olomoucine/roscovitine lead structure were synthesized and evaluated for their ability to inhibit starfish oocyte CDK1/cyclin B, neuronal CDK5/p35 and erk1 kinases in purified extracts. olomoucine 60-70 cyclin dependent kinase 1 Homo sapiens 174-178 10527623-8 1999 Olomoucine and roscovitine, the potent p34(cdc2) and CDK2 inhibitors, effectively blocked CD437-mediated cyclin A- and B-dependent kinase activation and prevented CD437-induced cell death. olomoucine 0-10 cyclin dependent kinase 1 Homo sapiens 43-47 10495356-3 1999 Intensive screening has lead to the recent identification of a series of chemical inhibitors of CDKs: olomoucine, roscovitine, purvalanol, CVT-313, flavopiridol, g-butyrolactone, indirubins, paullones and staurosporine. olomoucine 102-112 cyclin dependent kinase 1 Homo sapiens 96-100 10094816-6 1999 Olomoucine, a potent p34(cdc2) and Cdk2 inhibitor, effectively blocked RA-mediated p34(cdc2) kinase activation and prevented RA-induced apoptosis. olomoucine 0-10 cyclin dependent kinase 1 Homo sapiens 25-29 10094816-6 1999 Olomoucine, a potent p34(cdc2) and Cdk2 inhibitor, effectively blocked RA-mediated p34(cdc2) kinase activation and prevented RA-induced apoptosis. olomoucine 0-10 cyclin dependent kinase 1 Homo sapiens 87-91 10500810-6 1999 Olomoucine (OC), flavopiridol (FP), butyrolactone I (BL) and their derivatives selectively inhibit CDKs and thus constrain tumor cell proliferation under in vitro and/or in vivo conditions. olomoucine 12-14 cyclin dependent kinase 1 Homo sapiens 99-103 9438385-5 1998 Olomoucine, a potent p34cdc2 inhibitor, effectively prevented Taxol-induced p34cdc2 kinase activation and subsequent apoptosis. olomoucine 0-10 cyclin dependent kinase 1 Homo sapiens 21-28 9438385-5 1998 Olomoucine, a potent p34cdc2 inhibitor, effectively prevented Taxol-induced p34cdc2 kinase activation and subsequent apoptosis. olomoucine 0-10 cyclin dependent kinase 1 Homo sapiens 76-83 9288122-1 1997 BACKGROUND: Olomoucine and roscovitine are novel compounds that are designed to inhibit cyclin-dependent kinases (e.g., Cdk2 and cdc2). olomoucine 12-22 cyclin dependent kinase 1 Homo sapiens 129-133 9288122-3 1997 The purpose of this study was to determine (1) whether olomoucine and roscovitine inhibit Cdk2 and cdc2 kinase activities of the human gastric cancer cell line SIIA and (2) whether olomoucine and roscovitine block cell proliferation and cell cycle progression. olomoucine 55-65 cyclin dependent kinase 1 Homo sapiens 99-103 9288122-7 1997 RESULTS: Olomoucine and roscovitine completely blocked Cdk2 and cdc2 activities in SIIA cells. olomoucine 9-19 cyclin dependent kinase 1 Homo sapiens 64-68 8799831-6 1996 We also show that treatment of metaphase-arrested HeLa cells with staurosporine and olomoucine, inhibitors of p34cdc2 and other protein kinases, rapidly induces reassembly of interphase nuclei and dephosphorylation of histone H1 without chromosome segregation. olomoucine 84-94 cyclin dependent kinase 1 Homo sapiens 110-117 9315091-4 1997 Cdc2 was identified as the kinase responsible for the mitotic threonine phosphorylation by (1) immunodepletion of the mitotic Sam68 kinase from cell lysates with anti-Cdc2 antibodies, (2) inhibition of Sam68 phosphorylation in vitro and in vivo by the cyclin-dependent kinase inhibitor olomoucine and (3) phosphorylation of Sam68 by purified Cdc2. olomoucine 286-296 cyclin dependent kinase 1 Homo sapiens 0-4 9300578-1 1997 We have studied the effects of olomoucine, a selective inhibitor of cdk2, cdc2 and MAP kinase, on the rate of proliferation and the cell cycle progression in human cancer cells in culture. olomoucine 31-41 cyclin dependent kinase 1 Homo sapiens 74-78 9046330-0 1997 Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. olomoucine 96-106 cyclin dependent kinase 1 Homo sapiens 68-72